Biodistribution studies of the 186Re complex of 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid in mice

Alyafei, Saleh; Tomiyoshi, Katsumi; Sarwar, M.; Ahmed, Kazi Mokim; Zhang, H.; Oriuchi, Noboru; Inoue, Takamichi; Endo, Keigo

doi:10.1097/00006231-199906000-00010

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alyafei et al studied the biodistribution properties of 186 Re-3-amino-1-hydroxypropylidene-1,1-biphosphonic acid (APD) in mice [82]. The greatest accumulation of 186 Re-APD was found in bone resulting in bone to blood ratios of 25 to 189.…”

Section: Tin-117m-dtpamentioning

confidence: 99%

Preface

Ercan¹,

Çağlar²

2000

CPD

View full text Add to dashboard Cite

A variety of radiopharmaceuticals have been introduced for the internal therapy of malignant and inflammatory lesions in nuclear medicine. In order to destroy the diseased tissues radionuclides with high linear energy transfer (LET) such as beta, alpha, Auger or low energy conversion electron emitters are needed. The range of beta particles is in mm's so they are effective for large tumors. The range of alpha particles is short, only a few cell diameters. Thus, they are effective in treating circulating malignant cells and micrometastases. The range of Auger and conversion electrons is <0.1 micro m. They are very effective in cell killing when they are carried across cell membrane into the nucleus to damage DNA. Appropriate ions, molecules and particles are labelled with such radionuclides and used as radiopharmaceuticals in many different applications. For an effective dose to be delivered high target to non target ratios must be attained. Monoclonal antibodies to specific antigens expressed on tumor cells have been developed to increase the uptake by malignant tissues by specific accumulation. Radiolabelled peptides such as somatostatin, small molecules such as metaiodo-benzylguanidine (MIBG) and many different nano-and micro-particles have been investigated. The effectiveness of therapy can be increased by direct locoregional administration of the radiopharmaceutical. This way the radiation effects are confined locally and the normal tissues are spared from radiation effects. In this review article selection criteria and characteristics of radionuclides and carrier ions, molecules and particles for various therapeutic applications will be discussed, including mainly the recent developments.

show abstract

Section: Tin-117m-dtpamentioning

confidence: 99%

Preface

Ercan¹,

Çağlar²

2000

CPD

View full text Add to dashboard Cite

show abstract

“…The diphosphonate ligands such as MDP (methylenediphosphonic acid) and HMDP (1-hydroxymethylene-1,1-diphosphonic acid) labeled with 99m Tc have been widely used as bone imaging agents. Rhenium ( 186 Re and 188 Re) complexes with diphosphonate ligands including MDP [4,5], HEDP (1-hydroxyethylidene-1,1-diphosphonic acid) [6][7][8][9][10][11][12], APD (3-amino-1-hydroxypropylidene-1,1-diphosphonic acid) [13], AEDP (1-amino-ethylenediphosphonic acid) [14] and ABP (4-amino-1-hydroxybutylidene-1,1-diphosphonic acid) [15] have been synthesized and are found to be good bone seeking agents similar to 99m Tc diphosphonate complexes. Technetium-diphosphonate complexes proved to be a mixture of polymeric complexes by HPLC analysis.…”

Section: Introductionmentioning

confidence: 99%

Analysis of ¹⁸⁸Re-EDTMP complexes by HPLC and ultrafiltration

Hashimoto¹,

Matsuoka²

2004

Radiochimica Acta

View full text Add to dashboard Cite

No-carrier-added 188 Re / Effect of carrier addition / EDTMP / Chromatography / UltrafiltrationSummary. High performance liquid chromatography (anionexchange, reversed-phase ion-pair and gel permeation chromatography) and ultrafiltration have been employed to analyze 188 Re-ethylenediamine-N,N,N ,N -tetrakis(methylenephosphonic acid) complexes ( 188 Re-EDTMP), prepared from the tin chloride reduction or sodium borohydride reduction in the presence or absence of rhenium carrier. The HPLC analysis showed that the 188 Re-EDTMP complexes were mixtures of components and the distribution of the components was dependent upon the total amount of rhenium present and the reducing agents (SnCl 2 , NaBH 4 ). The ultrafiltration analysis showed that the distribution of nominal molecular weight of 188 Re-EDTMP was dependent upon the presence of rhenium carrier and the reducing agents. In addition, it was found that the proportion of chemical species with bigger molecular weight in no-carrier-added 188 Re(SnCl 2 )-EDTMP was larger than that in carrier-added 188 Re(SnCl 2 )-EDTMP.

show abstract